GlucoTrack, Inc. GCTK
0.19 USD 0.00 (+0.00%)
As ofNov 18, 2026, 2:52 PM EST
0.187 Day range 0.187
0.187 52-week range 207.00
- YTD
- -99.84%
- 1 year
- -99.88%
News
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares rose 211.2% to $1.88 during Monday's regular session. The company's market cap stands at $62.2 million. BeyondSpring (NASDAQ:BYSI) stock moved…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 16.1% to $0.92 during Thursday's after-market session. The company's market cap stands at $2.2 million. CareDx (NASDAQ:CDNA) stock rose 15.0% to…
businesswire.com Glucotrack, Inc. Announces Reverse Stock Split RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Glucotrack Announce Reverse Stock Split.
gurufocus.com Glucotrack, Inc. Announces Pricing of $3 Million Public Offering Glucotrack, Inc. (NASDAQ: GCTK) (âGlucotrackâ or the âCompanyâ) today announced the pricing of a âbest effortsâ public offering of 169,388 shares of
businesswire.com Glucotrack, Inc. Announces Pricing of $3 Million Public Offering RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Glucotrack, Inc. Announces Pricing of $3 Million Public Offering.
benzinga.com Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket Shares of GlucoTrack Inc (NASDAQ:GCTK) rose sharply in pre-market trading following the announcement that its subsidiary, Lokahi Therapeutics, signed its first external, fee-for-service partnership.
businesswire.com Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Lōkahi CEO Erik Emerson outlines LT-100 progress, ai² platform growth, and a strategy to discover, advance, and monetize assets.
gurufocus.com Lōkahi Therapeutics™ Continues ai² Pipeline™ Division Collaboration with The University of Alabama to Advance Asset Evaluation and Biopharma Talent LÅkahi Therapeuticsâ¢, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced that The University of Alabama's Culverhouse College of Business will
gurufocus.com Glucotrack Announces $11.5 Million Financing Glucotrack, Inc. (NASDAQ: GCTK) (âGlucotrackâ or the âCompanyâ) today announced definitive agreements for convertible notes with an aggregate principal
businesswire.com Glucotrack Announces $11.5 Million Financing RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)-- #Glucotrack--Glucotrack announces $11.5M convertible note financing, including new capital and note rollover, to support strategic growth.
businesswire.com Glucotrack, Inc. Announces Reverse Stock Split RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Glucotrack (Nasdaq: GCTK) announced a 1-for-15 reverse stock split effective August 31, 2026, to support Nasdaq listing compliance.
businesswire.com Glucotrack Achieves Key Compliance Milestone and Advances Strategic Transformation RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--"We are approaching the months ahead with confidence, urgency, and a clear sense of purpose," said Erik Emerson, CEO of Glucotrack.
globenewswire.com E.F. Hutton & Co. Acts as Exclusive Financial Advisor for $5.5 Million Financing for Glucotrack NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), a leading investment banking and financial advisory firm, today announced that it acted as exclusive financial advisor…
businesswire.com Glucotrack Announces $5.5 Million Financing RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Glucotrack, Inc. (NASDAQ: GCTK) ("Glucotrack" or the "Company") today announced definitive agreements for approximately $5.5 million in financing…
businesswire.com Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Glucotrack (NASDAQ: GCTK) today announced the continued expansion of the ai² Futures Lab™ operated through its wholly owned subsidiary, Lōkahi…
businesswire.com Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Lōkahi Therapeutics™ Inc., a wholly owned subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced progress in its LT-100 development…
globenewswire.com E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note Financing NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), a leading investment banking and financial advisory firm, today announced that it served as exclusive financial advisor…
globenewswire.com Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives RUTHERFORD, N.J. and SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), together with its operating business Lōkahi Therapeutics™…
globenewswire.com UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and…
globenewswire.com Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and…
globenewswire.com Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform RUTHERFORD, N.J., July 08, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical technology company focused on the design, development, and…
globenewswire.com Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association's 2026 Scientific Sessions RUTHERFORD, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and…
